• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

    4/15/25 7:59:22 AM ET
    $TXMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TXMD alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Walker Marlan D

    (Last) (First) (Middle)
    951 YAMATO ROAD
    SUITE 220

    (Street)
    BOCA RATON FL 33431

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    TherapeuticsMD, Inc. [ TXMD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    04/14/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/14/2025 P 490 A $0.9985 73,639 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Marlan D. Walker 04/15/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $TXMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXMD

    DatePrice TargetRatingAnalyst
    3/11/2022$3.00 → $2.50Buy
    HC Wainwright & Co.
    11/12/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $TXMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TherapeuticsMD Announces Full Year 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended Dec

      3/27/25 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Third Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and diluted common share, for the third quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $547 thousand for the third quarter of 2024, a

      11/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Second Quarter 2024 Financial Results

      TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and diluted common share, for the second quarter of 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $234 thousand for the second quarter of 2024, a

      8/12/24 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thompson Tommy G bought $326 worth of shares (325 units at $1.00), increasing direct ownership by 2% to 14,779 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:38 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $489 worth of shares (490 units at $1.00), increasing direct ownership by 0.67% to 73,639 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/15/25 7:59:22 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Walker Marlan D bought $1,994 worth of shares (2,303 units at $0.87), increasing direct ownership by 3% to 73,149 units (SEC Form 4)

      4 - TherapeuticsMD, Inc. (0000025743) (Issuer)

      4/10/25 4:29:49 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-6) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 12/28/2021. Application Category: NDA, Application Number: 210132, Application Classification: Efficacy

      12/29/21 7:23:57 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for IMVEXXY issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug IMVEXXY (SUPPL-2) with active ingredient ESTRADIOL has changed to 'Approval' on 11/16/2021. Application Category: NDA, Application Number: 208564, Application Classification: Labeling

      11/17/21 4:38:32 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BIJUVA issued to THERAPEUTICSMD INC

      Submission status for THERAPEUTICSMD INC's drug BIJUVA (SUPPL-3) with active ingredient ESTRADIOL; PROGESTERONE has changed to 'Approval' on 06/22/2021. Application Category: NDA, Application Number: 210132, Application Classification: Labeling

      6/24/21 5:13:50 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Financials

    Live finance-specific insights

    See more
    • TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

      - Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding indebtedness under Sixth Street facility and redeem all outstanding preferred equity - - TXMD is eligible to receive up to $30.0 million in milestone payments and a minimum of $42.6 million in royalty payments - TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-lis

      1/3/23 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Third Quarter 2022 Financial Results

      - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the third quarter ended September 30, 2022. "Our products continue to be adopted by healthcare providers and patients, and we continue to believe that they represent a significant opportunity. Our prescriber bases grew, and we added around 1,500 new prescribers for ANNOVERA and around 1,600 for IMVEXXY. Total quarterly prescriptions for both products remained relatively stable compared to the second

      11/14/22 4:05:00 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Announces Second Quarter 2022 Financial Results

      - Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today reported financial results for the Second Quarter ended June 30, 2022. "We saw solid revenue growth during the quarter, with an increase of 24% over the prior year period, while also experiencing a 21% decrease in operating expenses. The U.S. Food and Drug Administration's recent approval of our supplemental new drug application for ANNOVERA has significantly enhanced our ability to meet demand for the product.

      8/15/22 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by TherapeuticsMD Inc.

      10-K/A - TherapeuticsMD, Inc. (0000025743) (Filer)

      4/30/25 5:00:11 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TherapeuticsMD Inc. filed SEC Form 8-K: Other Events

      8-K - TherapeuticsMD, Inc. (0000025743) (Filer)

      4/9/25 6:30:57 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by TherapeuticsMD Inc.

      10-K - TherapeuticsMD, Inc. (0000025743) (Filer)

      3/27/25 4:50:03 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by TherapeuticsMD Inc.

      SC 13G - TherapeuticsMD, Inc. (0000025743) (Subject)

      11/12/24 4:40:08 PM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

      SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

      11/17/23 9:28:51 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by TherapeuticsMD Inc. (Amendment)

      SC 13D/A - TherapeuticsMD, Inc. (0000025743) (Subject)

      6/30/23 8:29:16 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $2.50 from $3.00 previously

      3/11/22 6:31:06 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TherapeuticsMD with a new price target

      HC Wainwright & Co. reiterated coverage of TherapeuticsMD with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      11/12/21 6:03:07 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TXMD
    Leadership Updates

    Live Leadership Updates

    See more
    • TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

      - Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman as the Company's Interim Co-Chief Executive Officers and Co-Principal Executive Officers. Dr. Bernick and Mr. Glickman succeed Mr. Hugh O'Dowd as the Company's Chief Executive Officer. Prior to this appointment, Dr. Bernick, the Company's co-founder, served as Chief Scientific and Medical Officer, and Mr. Glickman served as Chief Business Officer. The Company also announced that the Board of Directors appointed The Honorable Tommy Thompson, w

      9/12/22 6:50:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors

      Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t

      8/8/22 8:45:00 AM ET
      $CVM
      $HSTO
      $TXMD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer

      - Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, today announced key leadership changes, including the appointment of Hugh O'Dowd, the Company's current President, as the Company's Chief Executive Officer and member of the board of directors. Mr. O'Dowd will succeed Robert G. Finizio, the Company's Co-founder and current Chief Executive Officer, effective on or before December 31, 2021. Mr. Finizio will continue with the Company and has been appointed Vice Chair of the Board of Directors. "I wan

      11/11/21 6:45:00 AM ET
      $TXMD
      Biotechnology: Pharmaceutical Preparations
      Health Care